Estrella Immunopharma, Inc.
$1.17
+0.41%Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -3.3).
Valuation inputs: P/E -3.3, earnings yield N/A, momentum +0.4%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE +1.3%, ROIC +1.3%).
Profitability stack: net margin 0.0%, ROE +1.3%, ROIC +1.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +426.3%, momentum +0.4%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Estrella Immunopharma, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Estrella Immunopharma, Inc. Fair Value Envelope
No Revenue Data
ESLA has not reported any revenue values in the available annual periods.
Estrella Immunopharma, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
ESLA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
ESLA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
ESLA has not reported any net profit margin values in the available annual periods.
Estrella Immunopharma, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Estrella Immunopharma, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Estrella Immunopharma, Inc. Street Expectations Map
No Target Data
No analyst price targets available for esla.
Estrella Immunopharma, Inc. Insider Positioning
During the last 12 months, insiders have purchased $3K worth of ESLA shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
2.1K
2.59K
0
0.00
+3K
+$3K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Xu Jiandong
Officer: Chief Financial Officer
$3K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $3K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
No Dividend Yield Data
ESLA has not reported any dividend yield values in the available annual periods.
esla Dividend History
Learning Layer
Related Guides
Build conviction on ESLA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.